Research in the January 2023 issue of the Journal of the National Comprehensive Cancer Network finds that immunotherapy from PD-1 inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high colorectal cancer.
Longer follow-up results from the investigational phase Ib/II OrigAMI-1 study evaluating amivantamab-vmjw, a bispecific antibody targeting epidermal growth factor receptor and MET, in combination with FOLFOX or FOLFIRI chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer were presented during a poster session at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
